News stories about Tabula Rasa Healthcare (NASDAQ:TRHC) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tabula Rasa Healthcare earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.3493336615369 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Tabula Rasa Healthcare (TRHC) traded up 2.22% on Friday, hitting $27.63. 52,889 shares of the stock traded hands. The stock’s market cap is $477.61 million. Tabula Rasa Healthcare has a 52-week low of $10.39 and a 52-week high of $28.53. The stock’s 50 day moving average price is $25.82 and its 200 day moving average price is $25.82.

Tabula Rasa Healthcare (NASDAQ:TRHC) last released its quarterly earnings results on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.06. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The business had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. The firm’s quarterly revenue was up 32.6% compared to the same quarter last year. On average, equities analysts expect that Tabula Rasa Healthcare will post $0.40 EPS for the current fiscal year.

Several equities research analysts recently commented on TRHC shares. Stifel Nicolaus reissued a “buy” rating and set a $16.00 price objective on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. UBS AG boosted their price objective on shares of Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, August 30th. Wells Fargo & Company lowered shares of Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $17.00 to $21.00 in a research note on Thursday, September 7th. Piper Jaffray Companies reissued an “overweight” rating and set a $29.00 price objective (up previously from $20.00) on shares of Tabula Rasa Healthcare in a research note on Wednesday, September 20th. Finally, Chardan Capital started coverage on shares of Tabula Rasa Healthcare in a research note on Monday, July 10th. They set a “buy” rating and a $19.50 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $21.67.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/06/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-tabula-rasa-healthcare-trhc-stock-price.html.

In other news, insider Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $14.20, for a total value of $113,600.00. Following the sale, the insider now directly owns 903,407 shares in the company, valued at approximately $12,828,379.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 24,000 shares of company stock worth $428,080 over the last 90 days. Company insiders own 45.80% of the company’s stock.

About Tabula Rasa Healthcare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Insider Buying and Selling by Quarter for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Stock Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related stocks with our FREE daily email newsletter.